Compare · IMNM vs MRK
IMNM vs MRK
Side-by-side comparison of Immunome Inc. (IMNM) and Merck & Company Inc. (MRK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IMNM and MRK operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $314.90B, about 124.6x IMNM ($2.53B).
- Over the past year, IMNM is up 110.6% and MRK is up 59.4% - IMNM leads by 51.2 points.
- MRK has been more active in the news (14 items in the past 4 weeks vs 7 for IMNM).
- MRK has more recent analyst coverage (25 ratings vs 13 for IMNM).
- Company
- Immunome Inc.
- Merck & Company Inc.
- Price
- $22.30+0.45%
- $127.48-0.14%
- Market cap
- $2.53B
- $314.90B
- 1M return
- +24.57%
- +10.60%
- 1Y return
- +110.62%
- +59.45%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 7
- 14
- Recent ratings
- 13
- 25
Immunome Inc.
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Latest IMNM
- CHIEF BUSINESS OFFICER Horn Kinney exercised 1,092 shares at a strike of $12.92 and sold $27,300 worth of shares (1,092 units at $25.00) as part of a pre-agreed trading plan (SEC Form 4)
- Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors
- Director Barchas Isaac sold $2,412,522 worth of shares (100,000 units at $24.13) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Medical Officer Lechleider Robert exercised 55,000 shares at a strike of $8.73 and sold $1,244,331 worth of shares (55,000 units at $22.62) as part of a pre-agreed trading plan (SEC Form 4)
- Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Director Barchas Isaac sold $4,393,024 worth of shares (201,050 units at $21.85) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Medical Officer Lechleider Robert exercised 55,000 shares at a strike of $8.73 and sold $1,091,662 worth of shares (55,000 units at $19.85) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Financial Officer Rosett Max sold $1,093,800 worth of shares (60,000 units at $18.23) as part of a pre-agreed trading plan and exercised 60,000 shares at a strike of $1.05 (SEC Form 4)
- SEC Form 4 filed by Director Swain Sandra M
- SEC Form 4 filed by Director Wagenheim Philip
Latest MRK
- Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia
- Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026
- KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy
- SEC Form 4 filed by Director Seidman Christine E
- SEC Form 4 filed by Director Karsanbhai Surendralal Lanca
- SEC Form 4 filed by Director Coe Mary Ellen
- Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4
- Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV
- FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)
- SEC Form 11-K filed by Merck & Company Inc.